A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Glembatumumab vedotin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estrone | Estrone may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estriol | Estriol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Glembatumumab vedotin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Glembatumumab vedotin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Glembatumumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Glembatumumab vedotin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Equol | Equol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Glembatumumab vedotin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Glembatumumab vedotin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Glembatumumab vedotin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Glembatumumab vedotin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Glembatumumab vedotin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glembatumumab vedotin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Glembatumumab vedotin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Glembatumumab vedotin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Glembatumumab vedotin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glembatumumab vedotin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glembatumumab vedotin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Glembatumumab vedotin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Glembatumumab vedotin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Glembatumumab vedotin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Glembatumumab vedotin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Glembatumumab vedotin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glembatumumab vedotin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glembatumumab vedotin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Glembatumumab vedotin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glembatumumab vedotin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Glembatumumab vedotin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Glembatumumab vedotin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glembatumumab vedotin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Glembatumumab vedotin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Glembatumumab vedotin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Glembatumumab vedotin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glembatumumab vedotin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glembatumumab vedotin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Glembatumumab vedotin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Glembatumumab vedotin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Glembatumumab vedotin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Glembatumumab vedotin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Glembatumumab vedotin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Glembatumumab vedotin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Glembatumumab vedotin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Glembatumumab vedotin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Glembatumumab vedotin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Glembatumumab vedotin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Glembatumumab vedotin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Glembatumumab vedotin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Glembatumumab vedotin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Glembatumumab vedotin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Glembatumumab vedotin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Glembatumumab vedotin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Glembatumumab vedotin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Glembatumumab vedotin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Glembatumumab vedotin. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Glembatumumab vedotin. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Glembatumumab vedotin. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Glembatumumab vedotin. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Glembatumumab vedotin. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Glembatumumab vedotin. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Glembatumumab vedotin. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Glembatumumab vedotin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Glembatumumab vedotin. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Glembatumumab vedotin. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Glembatumumab vedotin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Glembatumumab vedotin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Glembatumumab vedotin. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Glembatumumab vedotin. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Glembatumumab vedotin. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Glembatumumab vedotin. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Glembatumumab vedotin. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Glembatumumab vedotin. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Glembatumumab vedotin. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Canakinumab. |